Spots Global Cancer Trial Database for An Open-label, Multi-center, Expanded Access Study of Pasireotide s.c. in Patients With Cushing's Disease.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: An Open-label, Multi-center, Expanded Access Study of Pasireotide s.c. in Patients With Cushing's Disease.
Official Title: An Open-label, Multi-center, Expanded Access Study of Pasireotide s.c. in Patients With Cushing's Disease (Seascape).
Study ID: NCT01582061
Conditions
Interventions
Study Description
Brief Summary: This study provided access to pasireotide sc in patients with Cushing's disease.and provided additional information for safety and efficacy of pasireotide s.c.
Detailed Description: Purpose of this study was to give access to pasireotide sc for patients with Cushing's disease as no medical treatment for Cushing's disease was approved at the time of the study initiation. The study population consisted of patients with persistent or recurrent Cushing's disease or patients with de novo Cushing's disease that were not considered candidates for pituitary surgery (poor surgery candidates, surgically unapproachable tumor, patients with no visible pituitary tumor, patients who refused surgery). A confirmed Cushing's disease diagnosis was required.
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Advanced Research, LLC, Peoria, Arizona, United States
St Josephs Hospital & Medical Center St Joes, Phoenix, Arizona, United States
University of California at Los Angeles UCLA Tiverton, Los Angeles, California, United States
LA Biomedical Research at Harbor UCLA Medical Center, Torrance, California, United States
Emory University School of Medicine, Atlanta, Georgia, United States
John H Stroger Jr Hospital of Cook County, Chicago, Illinois, United States
University of Maryland Medical Center, Baltimore, Maryland, United States
Diabetes and Endocrinology Associates, PC, Omaha, Nebraska, United States
University of Nebraska Medical Center, Omaha, Nebraska, United States
University of New Mexico Hospital UNM, Albuquerque, New Mexico, United States
Mount Sinai School of Medicine, New York, New York, United States
Oregon Health and Science University OHSU 5, Portland, Oregon, United States
University of Pennsylvania Medical Center Univ Penn, Philadelphia, Pennsylvania, United States
Allegheny Endocrinology Associates, Pittsburgh, Pennsylvania, United States
Mid South Endocrine Associates, Nashville, Tennessee, United States
Vanderbilt University Medical Center, Nashville, Tennessee, United States
Swedish Cancer Institute Swedish Cancer Institute (SC), Seattle, Washington, United States
Novartis Investigative Site, Fortaleza, CE, Brazil
Novartis Investigative Site, Londrina, PR, Brazil
Novartis Investigative Site, Rio de Janeiro, RJ, Brazil
Novartis Investigative Site, Porto Alegre, RS, Brazil
Novartis Investigative Site, Joinville, SC, Brazil
Novartis Investigative Site, Sao Paulo, SP, Brazil
Novartis Investigative Site, São Paulo, SP, Brazil
Novartis Investigative Site, Prague 2, Czech Republic, Czechia
Novartis Investigative Site, Aachen, , Germany
Novartis Investigative Site, Augsburg, , Germany
Novartis Investigative Site, Berlin, , Germany
Novartis Investigative Site, Berlin, , Germany
Novartis Investigative Site, Erlangen, , Germany
Novartis Investigative Site, Frankfurt, , Germany
Novartis Investigative Site, Frankfurt, , Germany
Novartis Investigative Site, Goettingen, , Germany
Novartis Investigative Site, Hamburg, , Germany
Novartis Investigative Site, Heidelberg, , Germany
Novartis Investigative Site, Leipzig, , Germany
Novartis Investigative Site, Mainz, , Germany
Novartis Investigative Site, Marburg, , Germany
Novartis Investigative Site, Muenchen, , Germany
Novartis Investigative Site, Oldenburg, , Germany
Novartis Investigative Site, Wurzburg, , Germany
Novartis Investigative Site, Athens, GR, Greece
Novartis Investigative Site, Thessaloniki, GR, Greece
Novartis Investigative Site, Athens, , Greece
Novartis Investigative Site, Thessaloniki, , Greece
Novartis Investigative Site, Seoul, Korea, Korea, Republic of
Novartis Investigative Site, Seoul, Korea, Korea, Republic of
Novartis Investigative Site, Seoul, , Korea, Republic of
Novartis Investigative Site, Seoul, , Korea, Republic of
Novartis Investigative Site, Ashrafieh, , Lebanon
Novartis Investigative Site, Bucharest, , Romania
Novartis Investigative Site, Bucuresti, , Romania
Novartis Investigative Site, Cluj, , Romania
Novartis Investigative Site, Iasi, , Romania
Novartis Investigative Site, Moscow, , Russian Federation
Novartis Investigative Site, Cordoba, Andalucia, Spain
Novartis Investigative Site, Granada, Andalucia, Spain
Novartis Investigative Site, Badalona, Catalunya, Spain
Novartis Investigative Site, Valencia, Comunidad Valenciana, Spain
Novartis Investigative Site, Valencia, Comunidad Valenciana, Spain
Novartis Investigative Site, Orense, Galicia, Spain
Novartis Investigative Site, Pontevedra, Galicia, Spain
Novartis Investigative Site, Palma De Mallorca, Islas Baleares, Spain
Novartis Investigative Site, Bangkok, , Thailand
Novartis Investigative Site, Songkla, , Thailand
Contact Details
Name: Novartis Pharmaceuticals
Affiliation: Novartis Pharmaceuticals
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
